PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1620533
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1620533
Prothrombin Complex Concentrate Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
The Global Prothrombin Complex Concentrate Market was valued at USD 2.1 billion in 2023 and is projected to grow at 9.4% CAGR from 2024 to 2032. This growth is primarily fueled by the rising prevalence of coagulation disorders and the increasing demand for plasma-derived therapies. The surge in coagulation disorders significantly contributes to the expansion of the PCC market worldwide. As conditions such as bleeding disorders and acquired coagulation disorders become more common, the need for effective and rapid treatment options like PCC has intensified. Factors such as vitamin K deficiency, liver diseases, and the widespread use of anticoagulant medications have further emphasized the importance of PCC, especially in emergency situations where quick intervention is essential.
The market is categorized by product type into 4-factor PCC and 3-factor PCC. In 2023, the 4-factor PCC segment led the market, generating approximately USD 1.2 billion. This product is often preferred in critical care settings due to its rapid onset of action and versatility in treating various conditions, including the reversal of direct oral anticoagulants. The strong endorsement of 4-factor PCC by clinical guidelines from various health organizations reinforces its position in coagulation-related treatments, further enhancing its market share.
From an application perspective, the segment for acquired coagulation factor deficiency captured nearly half of the market share in 2023. This type of disorder, often linked to conditions such as vitamin K deficiency or the effects of anticoagulant therapies, is more prevalent than congenital disorders. This higher incidence drives the demand for PCC in clinical settings where prompt treatment is essential, particularly during surgeries or trauma cases. North America emerged as the leading region in the PCC market in 2023, with revenues amounting to USD 788.3 million and expectations to reach USD 1.7 billion by 2032. The increasing prevalence of coagulation disorders, particularly in older populations, is a significant driver of PCC demand. Moreover, the advanced healthcare infrastructure in the U.S. and Canada supports the effective use and monitoring of PCC treatments, ensuring patients receive timely and efficient care.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $2.1 Billion |
| Forecast Value | $4.7 Billion |
| CAGR | 9.4% |
This growing market landscape highlights the importance of PCC in managing coagulation disorders and enhancing patient outcomes.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increased incidence of coagulation disorders
- 3.2.1.2 Growing demand for plasma-related therapies
- 3.2.1.3 Technological innovations
- 3.2.1.4 Advancements in research and development
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Intense competition from alternatives
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Reimbursement scenario
- 3.7 Pricing analysis
- 3.7.1 By region
- 3.7.2 By product
- 3.8 Future market trends
- 3.9 Patent analysis
- 3.10 Profit margin analysis
- 3.11 Pipeline analysis
- 3.12 Clinical trial landscape
- 3.13 Gap analysis
- 3.14 Porter's analysis
- 3.15 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 4-factor PCC
- 5.3 3-factor PCC
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Acquired coagulation factor deficiency
- 6.3 Congenital coagulation factor deficiency
- 6.4 Other applications
Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Ambulatory surgical centers
- 7.4 Other end users
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 CSL
- 9.2 Baxter
- 9.3 Emergent BioSolutions
- 9.4 Grifols Biologicals
- 9.5 Intas Pharmaceuticals
- 9.6 Kedrion Biopharma
- 9.7 LFB Group
- 9.8 Octapharma
- 9.9 Pfizer
- 9.10 Prothya Biosolutions
- 9.11 Takeda Pharmaceuticals
